Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink

Translated title of the contribution: Our experience with targeted therapy in glioblastoma multiforme

Kiss Edina, Lahm Erika, Vachaja József, Nagy Péter, Bazsó Péter, Fekete Zsolt, Nagy Z. Takácsi, Pápai Zsuzsanna

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.

Original languageHungarian
Pages (from-to)264-268
Number of pages5
JournalMagyar Onkologia
Volume57
Issue number4
Publication statusPublished - 2013

Fingerprint

Glioblastoma
temozolomide
Therapeutics
Combination Drug Therapy
Brain Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Radiation
Biopsy
Recurrence
Survival
Antibodies
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Edina, K., Erika, L., József, V., Péter, N., Péter, B., Zsolt, F., ... Zsuzsanna, P. (2013). Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink. Magyar Onkologia, 57(4), 264-268.

Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink. / Edina, Kiss; Erika, Lahm; József, Vachaja; Péter, Nagy; Péter, Bazsó; Zsolt, Fekete; Takácsi, Nagy Z.; Zsuzsanna, Pápai.

In: Magyar Onkologia, Vol. 57, No. 4, 2013, p. 264-268.

Research output: Contribution to journalArticle

Edina, K, Erika, L, József, V, Péter, N, Péter, B, Zsolt, F, Takácsi, NZ & Zsuzsanna, P 2013, 'Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink', Magyar Onkologia, vol. 57, no. 4, pp. 264-268.
Edina K, Erika L, József V, Péter N, Péter B, Zsolt F et al. Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink. Magyar Onkologia. 2013;57(4):264-268.
Edina, Kiss ; Erika, Lahm ; József, Vachaja ; Péter, Nagy ; Péter, Bazsó ; Zsolt, Fekete ; Takácsi, Nagy Z. ; Zsuzsanna, Pápai. / Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink. In: Magyar Onkologia. 2013 ; Vol. 57, No. 4. pp. 264-268.
@article{ff9de4cb0900467789b3f760162503ea,
title = "Glioblastoma multiform{\'e}ban szenved{\~o} betegek c{\'e}lzott ter{\'a}pi{\'a}s kezel{\'e}s{\'e}vel szerzett tapasztalataink",
abstract = "Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.",
keywords = "AVAglio, Bevacizumab, Glioblastoma multiforme, Temozolomide",
author = "Kiss Edina and Lahm Erika and Vachaja J{\'o}zsef and Nagy P{\'e}ter and Bazs{\'o} P{\'e}ter and Fekete Zsolt and Tak{\'a}csi, {Nagy Z.} and P{\'a}pai Zsuzsanna",
year = "2013",
language = "Hungarian",
volume = "57",
pages = "264--268",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink

AU - Edina, Kiss

AU - Erika, Lahm

AU - József, Vachaja

AU - Péter, Nagy

AU - Péter, Bazsó

AU - Zsolt, Fekete

AU - Takácsi, Nagy Z.

AU - Zsuzsanna, Pápai

PY - 2013

Y1 - 2013

N2 - Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.

AB - Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.

KW - AVAglio

KW - Bevacizumab

KW - Glioblastoma multiforme

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84899594778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899594778&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 264

EP - 268

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -